Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
OKYO Pharma Limited OKYO
$1.59
+$0.01 (0.63%)
На 18:05, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
42233606.00000000
-
week52high
7.00
-
week52low
1.10
-
Revenue
0
-
P/E TTM
-6
-
Beta
-0.02480900
-
EPS
-0.88000000
-
Last Dividend
0.00000000
-
Next Earnings Date
07 мая 2023 г. в 08:40
Описание компании
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| CERRONE GABRIELE M | A | 548981215 | 5800000 | 19 мая 2022 г. |
| CERRONE GABRIELE M | A | 62500 | 37500 | 19 мая 2022 г. |
| JACOB GARY S | A | 12500 | 12500 | 19 мая 2022 г. |
| CERRONE GABRIELE M | A | 25000 | 25000 | 17 мая 2022 г. |
| CERRONE GABRIELE M | A | 544806215 | 1625000 | 17 мая 2022 г. |
Новостная лента
OKYO Pharma eyes progress for OK-101 in 2023, releases interim results
Proactive Investors
30 дек 2022 г. в 04:48
OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO) has released its interim results for the six months ended 30 September 2022, a period in which its primary focus was on the development of its Dry Eye Disease (DED) drug, OK-101.
OKYO Pharma receives US FDA license to start Phase 2 study
Proactive Investors
22 дек 2022 г. в 02:57
OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO) said its dry eye disease treatment has received its investigational new drug (IND) application from the US Food and Drug Administration (FDA) to initiate a phase 2 study. First-in-human clinical studies of OK-101 are expected to open for enrolment in the first quarter of 2023, the biopharmaceutical company said.
OKYO Pharma applies for the go ahead for phase II trial of its dry eye disease treatment
Proactive Investors
21 ноя 2022 г. в 02:40
OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO) said it had filed an investigational new drug application with the US authorities for OK-101, its putative treatment for dry eye disease. It plans to carry out a phase II trial after being allowed to skip the initial safety phase by Food & Drug Administration.
OKYO Pharma to work with AmbioPharm on dry eye IND filing
Proactive Investors
30 авг 2022 г. в 03:11
OKYO Pharma said it will work with US group AmbioPharm on the investigational new drug (IND) filing of dry eye disease (DED) treatment OK-101. A US filing is expected in the final quarter of 2022, OKYO reiterated today with a first human trial early scheduled for early in 2023 OKYO added this will be a phase 2 trial, skipping the normal phase 1 study, as the drug is administered topically.